Brief: Calidi Biotherapeutics Announces Issuance Of New US Patent for Novel Supernova Technology Platform
20/11/2023 12:26
Nov 20 (Reuters) - Calidi Biotherapeutics Inc CLDI.A :
* CALIDI BIOTHERAPEUTICS ANNOUNCES ISSUANCE OF NEW U.S.
PATENT
COVERING NOVEL SUPERNOVA TECHNOLOGY PLATFORM AND UPDATES
ANTICIPATED CLINICAL MILESTONES
* CALIDI BIOTHERAPEUTICS INC - LOOK FORWARD TO INITIATING
OUR
FIRST-IN-HUMAN CLINICAL TRIAL OF OUR OFF--SHELF AND ALLOGENEIC
THERAPY IN 2024
Source text for Eikon: ID:nBw2RHzSKa
Further company coverage: CLDI.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma